Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:2226
Name myeloproliferative neoplasm
Definition A myeloid neoplasm that is characterized by a group of slow growing blood cancers in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood.
Source DiseaseOntology.org
Alt Ids DOID:6002
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myeloproliferative neoplasm

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 rearrange Dovitinib myeloproliferative neoplasm sensitive detail...
JAK2 V617F BMS-911543 myeloproliferative neoplasm sensitive detail...
JAK2 V617F Gandotinib myeloproliferative neoplasm predicted - sensitive detail...
JAK2 V617F Ropeginterferon myeloproliferative neoplasm sensitive detail...
JAK2 V617F C220 myeloproliferative neoplasm predicted - sensitive detail...
JAK2 V617F C220 + Ruxolitinib myeloproliferative neoplasm predicted - sensitive detail...
JAK2 V617F LGH447 + Ribociclib + Ruxolitinib myeloproliferative neoplasm sensitive detail...
JAK2 V617F IMG-7289 myeloproliferative neoplasm sensitive detail...
JAK2 V617F IMG-7289 + Ruxolitinib myeloproliferative neoplasm predicted - sensitive detail...
JAK2 V617F Crizotinib myeloproliferative neoplasm sensitive detail...
JAK2 V617F Flonoltinib maleate myeloproliferative neoplasm sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00074490 Phase II Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Sulfate Fludarabine Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Terminated USA 0
NCT01644110 Phase Ib/II Pomalidomide + Ruxolitinib Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC) Active, not recruiting DEU 0
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Terminated USA | DNK 0
NCT02556931 Phase II Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed USA 0
NCT02677922 Phase Ib/II Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy Active, not recruiting USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 2
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Terminated USA 0
NCT02890758 Phase I Nogapendekin alfa inbakicept Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT03011372 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) Completed USA | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT 1
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03386513 Phase Ib/II IMGN632 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT03471260 Phase Ib/II Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Recruiting USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03531736 Phase I Rituximab Cyclophosphamide + Fludarabine T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Active, not recruiting USA 0
NCT03807063 Phase I Rimiducid Rivogenlecleucel Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04016116 Phase II Pembrolizumab + Ruxolitinib Pembrolizumab Dual PD-1 and JAK2 Inhibition in Hematological Malignancies Withdrawn USA 0
NCT04022785 Phase I Azacitidine + PLX51107 PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT04089449 Phase I PRT811 A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis Completed USA 0
NCT04092179 Phase Ib/II Enasidenib + Venetoclax Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Terminated CAN 0
NCT04103645 Phase II Vactosertib Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients Terminated USA 0
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed USA 0
NCT04281498 Phase II Enasidenib + Ruxolitinib Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Completed USA | CAN 0
NCT04282187 Phase II Decitabine + Fedratinib Decitabine + Ruxolitinib Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Recruiting USA 0
NCT04493138 Phase Ib/II Azacitidine + Quizartinib Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Recruiting USA 0
NCT04493164 Phase II CPX-351 + Ivosidenib Ivosidenib CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04637009 Phase I TAS1553 A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms Terminated USA | CAN 0
NCT04953780 Phase I Calaspargase pegol-mknl + Cytarabine + Idarubicin 2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML Active, not recruiting USA 0
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Withdrawn USA 0
NCT05074355 Phase II Azacitidine + Venetoclax Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms Recruiting CAN 0
NCT05107856 Phase I PRT1419 A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies Terminated USA 0
NCT05127174 Phase Ib/II Fedratinib Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Active, not recruiting USA 0
NCT05223920 Phase II IMG-7289 Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms Completed USA | NZL | ITA | GBR | DEU | AUS 1
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Recruiting USA 0
NCT05444530 Phase I Ipilimumab + VAC85135 A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms Active, not recruiting USA | GBR 0
NCT05524857 Phase I Decitabine + Fedratinib Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) Terminated USA 0
NCT05823571 Phase I Itacitinib Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Recruiting USA 0
NCT06284460 Phase Ib/II ASTX029 ASTX029 + Decitabine and Cedazuridine Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms Withdrawn USA 0
NCT06291987 Phase I Ivosidenib + Ruxolitinib Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) Recruiting USA 0
NCT06523556 Phase Ib/II Axatilimab Axatilimab + Azacitidine Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT06597734 Phase II Decitabine and Cedazuridine + Olutasidenib Azacitidine + Olutasidenib Decitabine + Olutasidenib A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm Not yet recruiting USA 0